Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Recombinant dna technique included in method of making a...
Reexamination Certificate
2005-06-28
2005-06-28
Chan, Christina (Department: 1644)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Recombinant dna technique included in method of making a...
C435S320100, C435S455000, C435S252300, C536S023500
Reexamination Certificate
active
06911321
ABSTRACT:
The invention provides isolated non-human primate Fc receptor polypeptides, the nucleic acid molecules encoding the Fc receptor polypeptides, and the processes for production of recombinant forms of the Fc receptor polypeptides, including fusions, variants, and derivatives thereof. The invention also provides methods for evaluating the safety, efficacy and biological properties of Fc region containing molecules using the non-human primate Fc receptor polypeptides.
REFERENCES:
patent: 4518584 (1985-05-01), Mark et al.
patent: 4737462 (1988-04-01), Mark et al.
patent: 5189014 (1993-02-01), Cowan, Jr.
patent: 5824487 (1998-10-01), Ravetch et al.
patent: 5877396 (1999-03-01), Ravetch et al.
patent: 6194551 (2001-02-01), Idusogie et al.
patent: 6676927 (2004-01-01), Ravetch
Simister, N. et al., “The structure and evolution of FcRn”,Non-Polymorphic Antigen Presentation Molecules, pp. 333-337.
Norsworthy, P. et al., “Overrepresentation of the FCγ Receptor Type IIA R131/R131 Genotype in Caucasoid Systemic Lupus Erythematosus Patients with Autoantibodies to Clq and Glomerulonephritis”,Arthritis&Rheumatism, vol. 42, No. 9, pp. 1828-1832 (Sep. 1999).
Namenuk A. et al., “Binding of Human IgG to Cynomolgus FcR,”,GenEmbl Database, National Center for Biotechnology Information, National Library of Medicine, NIH, Accession No. AF485812 (Mar. 2002).
NCBI database, Accession No. L03418 (Porges et al., May 8, 1993).
Benincosa, L. et al., “Pharmacokinetics and Pharmacodynamics of a Humanized Monoclonal Antibody to Factor IX in Cynomolgus Monkeys”,The Journal of Pharmacology and Experimental Therapeutics, vol. 292, No. 2, pp. 810-816 (Feb. 2000).
Brok, H. et al., “Prophylactic and therapeutic effects of a humanized monoclonal antibody against the IL-2 receptor (DACLIZUMAB) on collagen-induced arthritis (CIA) in rhesus monkeys”,Clinical and Experimental Immunology, 124:134-141 (2001).
Clynes, R. et al., “Fc receptors are required in passive and active immunity to melanoma”,Proc. Natl. Acad. Sci. USA, vol. 95, No. 2, pp. 652-656 (Jan. 20, 1998).
Fishwild, D. et al., “Differential Effects of Administration of a Human Anti-CD4 Monoclonal Antibody, HM6G, in Nonhuman Primates”,Clinical Immunology, vol. 92, No. 2, pp. 138-152 (1999).
Ghetie, V. et al., “Multiple Roles for the Major Histocompatibility Complex Class I-Related Receptor FcRn”,Annual Review of Immunology, 18:739-766 (2000).
Glennie, M. et al., “Clinical trials of antibody therapy”,Immunology Today, vol. 21, No. 8, pp. 403-411 (Aug. 2000).
Gobburu, J. et al., “Pharmacokinetics/Dynamics of 5c8, a Monoclonal Antibody to CD154 (CD40 Ligand) Suppression of an Immune Response in Monkeys”,The Journal of Pharmacology and Experimental Therapeutics, vol. 286, No. 2, pp. 925-930 (1998).
Hamawy, M. et al., “Immunotoxin FN18-CRM9 Induces Stronger T Cell Signaling Than Unconjugated Monoclonal Antibody FN18”,Transplantation, vol. 72, No. 3, pp. 496-503 (Aug. 15, 2001
Hart, T. et al., “Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys”,The Journal of Allergy and Clinical Immunology, vol. 108, No. 2, pp. 250-257 (Aug. 2001).
Kao, F. et al., “Genetics of Somatic Mammalian cells, VII. Induction and Isolation of Nutritional Mutants in Chinese Hamster Cells”,Proc. Natl. Acad. Sci. USA, vol. 60, No. 4, pp. 1275-1281 (Aug. 1968).
Kim, J. et al., “Mapping the site on human IgG for binding of the MHC class I-related receptor, FcRn”,European Journal of Immunology, 29:2819-2825 (1999).
Küester, H. et al., “Characterization and Expression of the Gene for the Human Fc Receptor γ Subunit”,The Journal of Biological Chemistry, vol. 265, No. 11, pp. 6448-6452 (Apr. 15, 1990).
Kurucz, I. et al., “Bacterially expressed FcγRIIb is soluble and functionally actie after in vitro refolding”,Immunology Letters, 75:33-40 (2000).
Lehrnbecher, T. et al., “Variant Genotypes of the Low-Affinity Fcγ Receptors in Two Control Populations and a Review of Low-Affinity Fcγ Receptor Polymorphisms in Control and Disease Populations”,Blood, vol. 94, No. 12, pp. 4220-4232 (Dec. 15, 1999).
Lin, Y. et al., “Preclinical Pharmacokinetics, Interspecies Scaling, and Tissue Distribution of a Humanized Monoclonal Antibody against Vascular Endothelial Growth Factors”,The Journal of Pharmacology and Experimental Therapeutics, vol. 288, No. 1, pp. 371-378 (1999).
Maxwell, K. et al., “Crystal structure of the human leukocyte Fc receptor, FcγRIIa”,Nature Structural Biology, vol. 6, No. 5, pp. 437-442 (May 1999).
Mihara, M. et al., “Humanized Antibody to Human Interleukin-6 Receptor Inhibits the Development of Collagen Arthritis in Cynomolgus Monkeys”,Clinical Immunology, vol. 98, No. 3, pp. 319-326 (Mar. 2001).
Mordenti, J. et al., “Comparisons of the Intraocular Tissue Distribution, Pharmacokinetics, and Safety of125I-Labelled Full-Length and Fab Antibodies in Rhesus Monkeys Following Intravitreal Administration”,Toxicologic Pathology, vol. 27, No. 5, pp. 536-544 (Sep.-Oct. 1999).
Mourad, G. et al., “Humanized IgG1 and IgG4 Anti-CD4 Monoclonal Antibodies”,Transplantation, vol. 65, No. 5, pp. 632-641 (Mar. 15, 1998).
Ory, P. et al., “Characterization of Polymorphic Forms of Fc Receptor III on Human Neutrophils”,The Journal of Clinical Investigation, vol. 83, No. 5, pp. 1676-1681 (May 1989).
Ory, P. et al., “Sequences of Complementary DNAs that Encode the NA1 and NA2 Forms of Fc Receptor III on Human Neutrophils”,The Journal of Clinical Investigation, vol. 84, No. 5, pp. 1688-1691 (Nov. 1989).
Poston, R. et al., “Effects of Humanized Monoclonal Antibody to Rhesus CD11a in Rhesus Monkey Cardiac Allograft Recipients”,Transplantation, vol. 69, No. 10, pp. 2005-2013 (May 27, 2000).
Radaev, S. et al., “The Structure of a Human Type III Fcγ Receptor in Complex with Fc”,The Journal of Biological Chemistry, vol. 276, No. 19, pp. 16469-16477 (May 11, 2001).
Ravetch, J. et al., “IgG Fc Receptors”,Annual Review of Immunology, vol. 19:275-290 (2001).
Reichert, J., “Monoclonal antibodies in the clinic”,Nature Biotechnology, vol. 19, No. 9, pp. 819-822 (Sep. 2001).
Richter, W. et al., “Animal Pharmacokinetics of the Tumor Necrosis Factor Receptor-Immunoglobulin Fusion Protein Lenercept and Their Extrapolation to Humans”,Drug Metabolism and Disposition, vol. 27, No. 1, pp. 21-25 (Jan. 1999).
Sampson, J. et al., “Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors”,PNAS, vol. 97, No. 13, pp. 7503-7508 (Jun. 20, 2000).
Sautès, C., “Structure and Expression of Fc Receptors (FcR)”,Cell-Mediated Effects of Immunoglobulins, Chap. 2, pp. 29-66 (1997).
Schuurman, J. et al., “The inter-heavy chain disulfide bonds of IgG4 are in equilibrium with intra-chain disulfide bonds”,Molecular Immunology, vol. 38, No. 1, pp. 1-8 (Jan. 2001).
Shinkura, H. et al., “Safety and kinetic properties of a humanized antibody to human interleukin-6 receptor in healthy non-human primates”,Toxicology, 122:163-170 (Oct. 19, 1997).
Sondermann, P. et al., “Crystal structure of the soluble form of the human Fcγ-receptor IIb: a new member of the immunoglobulin superfamily at 1.7 Å resolution”,The EMBO Journal, vol. 18, No. 5, pp. 1095-1103 (Mar. 1, 1999).
Sondermann, P. et al., “The 3.2-Å crystal structure of the human IgG1 Fc fragment-FcγRIII complex”,Nature, 406:267-273 (Jul. 20, 2000).
Spiegelberg, H., “Biological Activities of Immunoglobulins of Different Classes and Subclasses”,Advances in Immunology, 19:259-294 (1974).
van der Pol, W. et al., “IgG receptor IIa alleles determine
Namenuk Angela K.
Presta Leonard G.
Belyavskyi Michali A
Chan Christina
Genentech Inc.
Merchant & Gould P.C.
LandOfFree
Non-human primate Fc receptors and methods of use does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Non-human primate Fc receptors and methods of use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Non-human primate Fc receptors and methods of use will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3493182